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ABSTRACT 
Due to their size (1-10 μm) microbubble-based drug delivery agents suffer from confinement to 
the vasculature, limiting tumour penetration and potentially reducing drug efficacy. Nanobubbles 
(NBs) have emerged as promising candidates for ultrasound triggered drug delivery, due to their 
small size allowing drug delivery complexes to take advantage of the enhanced permeability and 
retention effect. In this study we describe a simple method for production of Nested-NBs, by 
encapsulation of NBs (~ 100 nm) within drug loaded liposomes. This method combines the 
efficient and well-established drug loading capabilities of liposomes, whilst utilizing NBs as an 
acoustic trigger for drug release. Encapsulation was characterized using Transmission Electron 
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Microscopy with an encapsulation efficiency of 22 ± 2 %. Nested-NBs demonstrated 
echogenicity using diagnostic B-mode imaging and acoustic emissions were monitored during 
high intensity focused ultrasound (HIFU) in addition to monitoring of model drug release. 
Results showed that although the encapsulated NBs were destroyed by pulsed HIFU (peak 
negative pressure 1.54 – 4.83 MPa), signified by loss of echogenicity and detection of inertial 
cavitation, no model drug release was observed. Changing modality to continuous wave (CW) 
HIFU produced release across a range of peak negative pressures (2.01 – 3.90 MPa), likely due 
to a synergistic effect of mechanical and increased thermal stimuli. Due to this, we predict that 
our NBs contain a mixed population of both gaseous and liquid core particles, which upon CW 
HIFU undergo rapid phase conversion, triggering liposomal drug release. This hypothesis was 
investigated using previously described models to predict the existence of droplets and their 
phase change potential and the ability of this phase change to induce liposomal drug release. 
 
1 Introduction 
Chemotherapy, in combination with surgery or radiotherapy, is one of the primary treatment 
methods for malignant tumors and can significantly increase patient survival rates. However, 
treatment efficacy is currently limited by the negative side-effects and drug resistance present 
during systemic delivery. 1 The ability to target and locally deliver chemotherapeutics would 
help to reduce toxic side-effects, but also increase drug efficacy and treatment effectiveness. 
Drug-loaded liposomes, such as Doxil and Onivyde, reduce the exposure of healthy tissues to 
drug and are currently approved for clinical use.  However, due to the lack of a triggered release 
mechanism in addition to hepatic and renal clearance, drug efficacy is not maximised.2 Methods 
for triggering release using mechanical and thermal approaches such as ultrasound (US) 3  and 
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near-infrared lasers 4 are currently being developed for improving controlled local release. The 
use of US is appealing due to its wide-spread availability, non-invasive nature and potential for 
image guidance during treatment. US imaging utilizes high-frequency sound waves that 
propagate through tissue and the back-scattered waves are used to construct an image. 
Microbubbles (MBs) are commonly used as ultrasound contrast agents (UCAs) due to their high 
acoustic-impedance mismatch with surrounding tissue, whilst their size of 1 - 10 μm allows 
facile circulation through the vasculature. MB stability is enhanced by using high molecular 
weight, low solubility gases such as perfluorocarbons 5 or Sulphur Hexafluoride (SF ) 6  as well 
as a coating, typically a phospholipid monolayer, protein or polymer 7–9. Recently, research has 
focused on the  potential use of MBs as theranostic agents. 10,11 MBs driven by an US field can 
enhance sonoporation in cell membranes, which has been shown to increase drug uptake.9,12–14  
Therapeutics can be incorporated with MBs in multiple ways including therapeutic gas 15 , direct 
attachment of drugs to the lipid shell 16 and attachment of drug-filled liposomes 17–19 which can 
be released by increasing US intensity. Surface functionalization of the MB shells can be used to 
provide molecular targeting 17 and improved stealth properties. 20 However, to increase tumor 
bio-distribution and take advantage of the enhanced permeation and retention (EPR) effect 
provided by the leaky vasculature, the drug delivery complex should be < 400 nm. 21,22 As such, 
nanobubbles (NBs), sub-micron bubbles typically 200 – 600 nm in diameter 23,24, are an 
attractive prospect for drug delivery and have shown increased tumor accumulation and retention 
compared to MBs. 25,26   We have previously reported the production and characterization of NBs 
using microfluidics 27 with others using methods such as mechanical agitation and sonication.28–
30 The inverse relationship between Laplace pressure and bubble radius leads to predicted 
lifetimes on the order of microseconds. 31,32 In spite of this NBs have demonstrated remarkable 
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stability 27,33,34 which has raised speculation as to their physical state and the nature of 
stabilization. 31,32,35,36 NBs provide US contrast enhancement at frequencies below their 
resonance and hence provide promise for diagnostic use. 37,38 Further, they have also been used 
for the delivery of therapeutics either by co-delivery 39 or by direct incorporation of their 
payload. 26,29,40,41 
In this paper we introduce Nested-Nanobubbles (Nested-NBs) as sub-micron US triggered 
drug delivery vehicles. Nested-NBs consist of an outer liposomal shell containing both the 
encapsulated drug payload and one or more NBs that can act as internal nuclei for an US 
triggered release.  The NBs were produced using microfluidics 27 and encapsulated together with 
calcein within liposomes via thin film rehydration. Encapsulation of NBs was demonstrated 
using Transmission Electron Microscopy (TEM) and Nested-NBs echogenicity characterized 
using clinical B-mode ultrasound imaging, which subsequently decreased after High Intensity 
Focused Ultrasound (HIFU) trigger. Nested-NBs were loaded with calcein to act as a model drug 
and for pulsed HIFU exposures, no release was observed. However, the use of a continuous wave 
US exposure triggered calcein release for free field peak negative pressure ranging from 2.01 ± 
0.10 MPa to 3.90 ± 0.10 MPa.  Our results suggest that the release mechanism is a synergistic 
effect of mechanical and thermal stimuli and that our NB populations contain a mixture of 
particles both their gaseous and liquid phases, the latter of which undergo a low-pressure phase-
change. This drug delivery vehicle provides the acoustic diagnostic properties of NBs combined 
with the therapeutic advantages offered by liposomes and with the additional benefit of an 




2.1 Microfluidic Production of Nano- and Microbubbles 
Nano- and microbubbles were prepared from a mixture of DPPC (1,2-dipalmitoyl-sn-glycero-
3-phosphocholine) and DPSE-PEG2000 (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000]) in a 95:5 molar ratio and a total lipid concentration of 2 
mg/mL (Avanti Polar Lipids, AL, US). Lipids were dissolved in a 1:1 mixture of Chloroform and 
Methanol and dried under Nitrogen to remove the solvent and subsequently resuspended in PBS 
solution containing 1 % (v/v) glycerol. The lipid solution was then combined with C F  (PFB) 
gas in a multiplexed microspray microfluidic device for bubble production as described in 
Peyman et al. 27  
2.2 Nanobubble Isolation  
NBs were passively isolated from MBs via flotation due intrinsic MB buoyancy. A spherical 
bubble in a medium has an ascension velocity, described by the Hadamard-Rybczynski equation 
(Equation 1).42 For a PFB bubble with radius of 1 μm it would take 47 minutes to travel 1 cm. 
For a bubble in the same medium with diameter of 150 nm it would take 840 minutes to travel 
the same distance and as such can be regarded as neutrally buoyant. After 1 hour, a syringe and 
fine needle was used to remove NB sample from the bottom of the vial and subsequently filtered 
through 800 nm PTFE membrane to remove any large bubbles. 




Where U is ascension velocity, g is gravitational acceleration (9.81 ms-1), R is radius, Δρ is 
difference in density between the medium and the core, μ is dynamic viscosity of water (8.9 x 
10-4 Pa s) , μ’ is dynamic viscosity of C4F10 (1.2 x 10-5 Pa s). 
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2.3 Nanobubble size and concentration determination 
Nanoparticle Tracking Analysis (NTA). Single particle tracking was used to analyse NB 
populations using NanoSight Nanoparticle Tracking Analysis (NanoSight NS300, Malvern 
Panalytical, UK). Samples were illuminated with a 488 nm laser and individual particles tracked 
using NTA 3.3 software. Samples were diluted 1:1000 in PBS prior to measurement and 
measurements repeated in triplicate. 
Resonant Mass Measurement (RMM). Resonant mass measurement (Archimedes, Malvern 
Panalytical, UK) was used to demonstrate and analyze populations of positively buoyant 
(bubbles) and negatively buoyant particles in NB solutions. Archimedes was equipped with a 
MicroH sensor capable of measurement of particle diameters of between 150 – 5000 nm and pre-
calibrated with 1 μm polystyrene beads (ThermoScientific Microsphere Size Standards 4010A) 
Samples were diluted 1:500 in PBS prior to measurements. During the measurement, NB sample 
was loaded initially for 120 seconds and analyzed at pressures of 3, 2 and 3 psi for sample, 
reference and experiment values. Limit of detection was set to 25 mHz to provide consistency for 
all measurements. Particle densities were set to 0.0112 and 1.3 g/mL for positively buoyant and 
negatively buoyant particles respectively, corresponding to the density of PFB gas and lipid 
vesicles.43  
2.4  Liposome and Nested-Nanobubble Production 
A combination of DSPC, Cholesterol and DSPE-PEG2000 were dried under Nitrogen in round 
bottom flasks in a 63:32:5 molar ratio at a total lipid concentration of 15 mg/mL The lipid film 
was resuspended in either PBS buffer for liposome production or with NBs at stock 
concentration for Nested-NB production and rehydrated via stirring for 1 hour. For calcein 
loading, solution pH adjusted using 10 M NaOH to pH 10.5 and calcein added to a final 
concentration of 100 mM prior to rehydration. Rehydrated lipid solution was homogenized via 
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extrusion by passing through a 400 nm PTFE membrane. Free calcein and NBs were removed 
via centrifugation at 17,000 g for 20 minutes, washed with PBS and centrifugation and washing 
were repeated once. (Scheme 1) 
 
Scheme 1.  Preparation of Nested-NBs by isolation of NBs via buoyancy, thin film rehydration 
of a lipid film and cleaning via centrifugation.  
2.5 Transmission Electron Microscopy 
For Transmission Electron Microscopy (TEM), samples were prepared in a phosphate free 
buffer and 5 uL of sample pipetted onto glow discharged carbon grids. After 30 seconds 
incubation, sample was washed with buffer and 5 uL of 1 % uranyl acetate added for 30 seconds, 
then removed and left to air dry. Images were taken at a range of magnifications ranging from 
11,000 to 46,000 x using a FEI T12 transmission electron microscope (FEI Tecnai T12, USA). 
Images were analyzed manually using ImageJ (NIH, US) to determine particle diameter. 
2.6 Encapsulation and Release Efficiency 
Fluorescence spectroscopy was used to quantify the release of calcein from within Nested-NBs 
and liposomes from ultrasound exposures. Due to the high concentration of encapsulated calcein 
within the liposomes, calcein fluorescence was initially quenched. However, when released from 
the liposome into the bulk medium, calcein concentration decreases and subsequently 
unquenches. Nested-NB and liposome samples were diluted 1:25 in PBS to increase sensitivity 
of the fluorescence assay. Sample fluorescence was measured using a microplate reader 
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(SpectraMax M2E, Molecular Devices, US) with excitation and emission wavelength of 460 and 
515 nm respectively. Nested-NB and LS sample fluorescence was measured for non-exposed 
samples (negative control), exposed sample and samples lysed with 0.1 % Triton-X (positive 
control) to calculate the percentage of calcein released from the sample. Percentage release was 
calculated by Equation 2, where FL , FL  and FL  are fluorescence intensities 
for HIFU exposed, positive and negative control samples respectively. 
 % Release = 100 x (FL − FL  )/(FL − FL ) (2) 
 
2.7 Ultrasound Imaging 
B-mode diagnostic US images of NB and Nested-NB populations were produced using a 3-8 
MHz linear array probe (V-Scan, GE Healthcare, IL, US). Samples were imaged in a wall-less 
agar flow phantom, produced by mixing 3 % by mass agar and 8 % by mass glycerol with 
degassed water 44. The mixture was heated in a microwave and manually stirred intermittently 
until a homogenous solution was produced. The mixture was poured into a 3D printed mould 
containing a 4 mm outer diameter tube and left to cool. The tube was removed after the agar had 
set and Luer lock fittings attached for sample loading. Mean grayscale intensity of B-mode 
images were calculated in the region of interest using MATLAB (Mathworks Inc, US). 
2.8 High Intensity Focused Ultrasound (HIFU) and Passive Cavitation Detection (PCD) 
A single element High Intensity Focused Ultrasound (HIFU) transducer was used for US 
mediated NB destruction. A 1.1 MHz center frequency HIFU transducer (H-102, Sonic 
Concepts, US) was used for all HIFU experiments. The transducer was connected to a +55 dB 
power amplifier (A300, E&I Ltd, US) via an impedance matching circuit. A computer-controlled 
function generator (33220A, Agilent, US) was used to provide sinusoidal burst cycles to the 
transducer. Free field pressure was measured using a membrane hydrophone (Precision Acoustic 
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Ltd, Dorchester, UK) with a 400 μm sensitive element, calibrated by the National Physics 
Laboratory (Middlesex, UK). 45 All pressures stated are based from their free field calibrations 
with errors of ± 0.1 MPa. The HIFU transducer was coupled to the sample using a coupling cone 
containing degassed MilliQ water. A TTL digital delay pulse generator (9524, Quantum 
Composers, MT, USA) was used to synchronize the HIFU pulse and data acquisition system. A 
broadband focused detection (Y-102, Sonic Concepts, WA, USA) was positioned in the central 
aperture of the HIFU transducer and co-aligned with its focal region. It was connected to a 5 
MHz high pass filter (Allen Avionics,US) and a 40 dB pre-amplifier (Spectrum 
GmbH,Germany). A 14-bit data acquisition (DAQ) card (M4i.4420-x8, Spectrum GmbH, 
Germany) was used to record acoustic emissions. A desktop PC was used to control all hard-
ware and post-processing using MATLAB.  For each HIFU pulse, 163 μs of cavitation data was 
recorded and Fast Fourier Transformed into the frequency domain. Frequency data was comb 
filtered to either remove harmonics, leaving only broadband emissions. 46 Additionally, the 
inverse comb filter was applied to remove broadband emissions, leaving only ultraharmonic 
emissions. Data was recorded for 0.5 s either side of the 5 s HIFU exposure with initial values 
before HIFU used as a noise baseline. To maximize the magnitude of acoustic emissions, the 
concentration of Nested-NBs and Liposomes were maintained as high as possible whilst 
remaining constant between the two samples at 1.56 x 1011 particles/mL.  
3 Results and Discussion 
3.1 Nanobubble Characterisation 
NBs were produced using the micro-fluidic micro-spray approach and separated from the 
microbubbles by floatation of the microbubble and collection of the sub-natent. NB populations 
were characterised using three separate techniques; Nanoparticle Tracking Analysis (NTA), 
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Resonance Mass Measurement (RMM) and Transmission Electron Microscopy (TEM). Using 
NTA the NB concentration and size, measured across five sample preparations, were found to be 
5.79 ± 0.66 x 1011 /mL, with a modal size of 106 ± 4 nm (Figure 1a). NBs were also analysed 
using RMM (Figure 1b) a technique that can distinguish between positively buoyant particles 
(i.e. ones that are less dense than the solution) and negatively buoyant particles (i.e. denser than 
the solution). RMM also measures the size and concentration of the positively and negatively 
buoyant particles. The average concentrations and sizes measured from 3 separate samples were 
found to be 1.17 ± 0.68 x 109 /mL and 3.54 ± 1.20 x 109 /mL with respective modal sizes of 212 
± 12 nm and 321 ± 32 nm for the positively and negatively buoyant particles respectively (Figure 
1b). The negatively buoyant population likely consists of a combination of lipid particles that 
were not converted into bubbles as well as potentially containing PFB droplets, that due to their 
small size have condensed from a gas into liquid PFB droplets. However, the limit of detection 
of the RMM system was around 200 nm, thus failing to determine the nature of the particles 
making-up the largest contribution to the NTA data circa 100 nm. Additionally, NBs were 
imaged using TEM and their size distribution analysed. A total of 252 NBs across 31 images 
were counted and their sizes analysed, demonstrating a log-normal distribution with a size of 120 
± 48 nm (Figure 1c), with a representative TEM image is shown in Figure 1d. A small proportion 
of < 100 nm particles were measured via TEM, again likely to be lipid vesicles or PFB droplets 
below the detection threshold for both NTA and RMM analysis. Comparison between the three 
measurement techniques used show agreement between both NTA and TEM results, in terms of 
their respective modal sizes and the population distributions. However, for RMM, the limit of 
detection is higher than that of the modal particle size, thus a large proportion of the NB 
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population is likely missing. Notwithstanding this, RMM is still useful for confirming the 
presence of sub-micron bubbles, as opposed to just particles. 
 
NBs were imaged using B-mode imaging (3 - 8 MHz Broadband, Linear Array, MI = 0.8) 
using a flow-phantom to assess their echogenicity at clinically relevant imaging parameters. NB 
 
Figure 1.  Characterisation of Nanobubbles using (a) Nanoparticle Tracking Analysis 
(NTA), (b) Resonant Mass Measurement (RMM) showing both (bi) Positively and (bii) 
Negatively buoyant particles and (c) transmission electron microscopy (TEM) with a 
representative image shown in (d).  































































concentration was measured via NTA and diluted to concentrations of ~ 109 – 1011 NBs/mL-1 to 
determine contrast enhancement across a range of concentrations. Mean Grayscale Intensity 
(MGI) of the B-mode images was measured in the region of interest (ROI) of the flow phantom 
(as shown in Figure 2ai) for each concentration and showed a linear increase in MGI with 
increasing concentration (Figure 2aii).  It is also notable that the MI used for this experiment was 
larger than is typically used for micron scale UCAs (< 0.3), as greater than this typically induces 
microbubble destruction. However, NBs were stable during imaging experiments. 
NBs were also exposed to high intensity focused ultrasound (HIFU) and the B-mode MGI 
measured prior to and post-exposure, to determine whether NB destruction had been achieved. 
The peak negative pressure (PNP) was varied between 1.06 – 6.75 MPa using a PRF of 1 kHz 
and 1 % duty cycle for a total of 5 seconds. MGI decreased exponentially with increasing 
pressure reaching a minimum MGI after exposure at 4.83 MPa (Figure 2b). Nanobubble 
destruction was also demonstrated using RMM, where positively buoyant particle concentration 
decreased by an order of magnitude, from 4.38 x 108  NBs/mL to 3.24 x 107 NBs/mL after HIFU 
exposure, whilst the negatively buoyant particle concentration remained unchanged (Figure 2c). 




Figure 2.  (ai) Representative clinical frequency B-mode (3-8 MHz Linear Array, MI = 0.8)  
images of NBs and PBS in a flow phantom and (aii) change in Mean Grayscale Intensity 
(MGI) for NBs with varying concentration. (b) MGI of B-mode images of NB sample after 
application of high intensity focused ultrasound (HIFU) with varying PNP. (c) 
Concentration of negatively buoyant and positively buoyant particles before and after HIFU 
exposure at PNP of 4.83 MPa with 1 % duty cycle, measured via RMM. 
3.2 Nested-NB Production and Characterisation 
Nested-NBs were produced by passive encapsulation of the NBs inside phospholipid 
liposomes. Calcein loaded at a concentration to give self-quenching was also encapsulated to 
simulate a model small molecule drug. After encapsulation, free calcein and small particles ( < 
200 nm), believed to be a combination of both un-encapsulated NBs and empty liposomes, were 
removed by centrifugation, as described in Section 2.4. The population distribution of the 
Nested-NBs post-cleaning is shown in Figure 3a.  After cleaning Nested-NBs mean size 
increased from 182.6 ± 0.2 nm to 318.9 ± 7.1 nm and there was a concomitant decrease in 
concentration from 1.82 ± 0.09 x 1012 particles/mL to 2.45 ± 0.10 x 1011 particles/mL (Figure 
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S2). Additionally, after cleaning the mean grayscale intensity of B-mode images of Nested-NBs 
decreased from 30.5 ± 1.9 to 11.3 ± 0.7 as would be expected with the removal of free NBs 
(Figure S3).  
The efficiency of NB encapsulation, within Nested-NBs, was determined using TEM. A total 
of 124 individual liposomes were analysed across 38 images, with 22 ± 2% of liposomes 
encapsulating single or multiple NBs. On average, each Nested-NB contained 1.29 ± 0.01 NBs. 
 
Figure 3. Nested-NB population distribution measured by (a) Nanoparticle Tracking 
Analysis and (b) Transmission Electron (TEM) microscopy, showing distribution for both 
the nested NB and the encapsulating liposome. (c) and (d): Representative TEM images of 
Nested-NBs showing two individual Nested-NBs and a larger field of view respectively. 
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Nested-NB size distribution measured via TEM is shown in Figure 3b, with populations for both 
their outer liposomal shell and encapsulated NBs analysed. Representative images are shown in 
(c) and (d), demonstrating clear encapsulation of a nesting particle within an outer liposomal 
shell.  Population distributions followed a normal distribution with modal sizes of nesting 
particles and liposomes at 140 ± 69 nm and of 251 ± 130 nm respectively. 
3.3 Ultrasound Triggered Release 
Nested-NBs were exposed to HIFU to provide a mechanism for triggered NB destruction and 
subsequent payload release. Initially, Nested-NBs and Liposome only controls were insonated at 
free-field PNPs of 1.54, 2.96 and 4.83 MPa for a total of 5 seconds with duty cycles of either 1 or 
50 %. Release profiles are shown in Figure 4a and 4b respectively. At these exposure parameters, 
no significant calcein release was observed from Nested-NBs compared to liposome only 
controls. To determine whether these exposures were inducing destruction of the encapsulated 
NBs, Nested-NBs were imaged using B-mode ultrasound before and after HIFU exposure. 
Nested-NBs initially demonstrated echogenicity, which after insonation at 4.83 MPa at 50 % 
duty cycle  decreased by 92.4 ± 5.6 % from 60.3 ± 2.4 to 4.6 ± 0.8, suggesting NB destruction 
(Figure 4b inset). 
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The lack of observed release from HIFU mediated NB destruction led us to further investigate 
the interaction between Nested-NBs and the applied HIFU field. Passive cavitation detection was 
used to observe acoustic emissions during insonation. Nested-NB, liposome and PBS samples 
were each exposed to HIFU, at the previously described parameters. Acoustic emissions were 
converted into the frequency domain by Fast Fourier Transform and the magnitude of the 
broadband noise and ultra-harmonic emissions were determined to quantify the occurrence of 
inertial cavitation (bubble destruction) and stable cavitation (bubble oscillation). Due to the high 
PNP, NB destruction was expected to occur during the initial pulse cycles of the HIFU exposure. 
To quantify the change in the magnitude of acoustic emissions over time, broadband and ultra-
harmonic emissions were cumulatively integrated with increasing pulse number and then 
normalised per pulse. Full temporal emissions for the whole exposure duration are shown in 
Figure S4. For both broadband  (Figure 5a) and ultra-harmonic (Figure 5b) emissions, Nested-
NBs demonstrate increased activity at the beginning of the exposure which decreased with 
  
Figure 4. Release profiles for Nested-NBs and Liposome controls after ultrasound exposure at 
PNPs ranging from 1.54 MPa to 4.83 MPa at (a) 1 % Duty Cycle and (b) 50 % Duty Cycle. 
Inset: Mean grayscale intensity of B-mode imaging of Nested-NBs before and after HIFU 

















































increasing pulse number to the value found for non-acoustically active liposomes. This suggests 
that the NBs present initially in the Nested-NB sample provide an increase in both broadband 
and harmonic emissions, as NBs undergo stable and inertial cavitation. As the HIFU exposure 
progresses, the broadband and harmonic emissions decrease until eventually by the end of the 
exposure the Nested-NB and liposome samples are indistinguishable from each other, with no 
NBs remaining. This is also in agreement with the near total loss of contrast shown by B-mode 
imaging (Figure 4b). Both Nested-NB and liposome samples demonstrated increased broadband 
and harmonic emissions compared to a PBS control, likely due to non-acoustically active 
liposomes providing cavitation nuclei. The relatively high value of the PBS control can be  
attributed to a combination of both cavitation induced within the solution and acoustic reflections 
from the sample holder due to the relatively high PNP. Due to the lack of release observed from 
 
  Figure 5. (a) Normalised Broadband Emissions and (b) Normalised Ultraharmonic Emissions 
measured using passive cavitation detection during insonation at 4.83 MPa and 50 % duty cycle 
for Nested-Nanobubbles, Liposomes and PBS samples. Data shows the acoustic emissions 
integrated over the number of pulses and then normalised per pulse. 
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Nested-NBs, it is possible that the detected inertial cavitation is occurring in the bulk solution, or 
that the encapsulated NBs are being destroyed but not capable of inducing drug release. 
By changing the modality of the HIFU exposure from pulsed to continuous wave, we found 
that Nested-NBs showed calcein release for PNPs ranging from 2.01-3.90 MPa with an exposure 
time of 5 s. Figure 6a shows the release profiles for both Nested-NBs (solid) and Liposomes 
(hashed). The amount of release increased with increasing PNP for both samples up to a 
maximum Nested-NB release of 52.9 ± 10.3 % with a corresponding Liposome only release of 
35.3 ± 9.2 %. Considering only the difference in release between Nested-NBs and Liposomes, a 
maximum difference of 26.2 ± 10.3 % was achieved at 2.96 MPa (Figure 6b).  The difference in 
release is comparable to the encapsulation efficiency of NBs within Nested-NBs of 22 ± 2 %, 
which would suggest that the efficacy of release of the Nested-NB is approaching 100 %. 
Increasing the PNP further led to a decrease in the difference in the release profiles. For the 
 
Figure 6. (a) Release profile of Nested-NBs and Liposome controls after continuous wave 
HIFU exposure at PNPs ranging from 2.01 – 3.90 MPa. (b) Difference in release of Nested-
NBs compared to Liposome controls. 
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Nested-NB sample, any release observed above that of the NB encapsulation efficiency, would 
likely be attributed to thermally induced release. Additionally, since no release was previously 
observed with pulsed HIFU exposures (Figure 4) the ability of continuous wave HIFU to induce 
release is helpful in identifying the release mechanism. Although NBs are present in the Nested-
NB sample, RMM (Figure 1b) identified that 79 ± 4 % of the population concentration consists 
of negatively buoyant particles. As such, it is reasonable to assume that a similar proportion of 
encapsulated particles within the Nested-NBs would be negatively buoyant. Additionally, due to 
the modal size of encapsulated particles (~140 nm) being less than the limit of detection of RMM 
(~ 200 nm), the existence of bubbles of this size cannot be confirmed. Due to the inverse 
relationship between the Laplace pressure and bubble radius (Equation 3), in addition to the 
density of the PFB gas core used in our experiments, it is increasingly likely that as particle size 
decreases, a sub-population of PFB droplets would exist. 
 Δ𝑃 = 2𝜎𝑟  (3) 
Where ΔP is pressure difference between inside and outside the particle, σ is surface tension of 
the interface and r is particle size. 
The bulk boiling point of PFB is -1.7 ° C however, confinement into either a bubble or droplet 
will elevate this boiling temperature due to the associated pressure increase. This elevation can 
be described by the Clausius-Clapeyron relation modified to include the Laplace effect as given 
in Equation 4. 47 
 T = 1T − RM Δ H ln 1 + 2𝜎𝑟 𝑃  (4) 
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Where T1 is the elevated boiling temperature, T  is boiling point (271.4K) at atmospheric 
pressure P0  (101.3 kPa), Mw is molecular weight of PFB (238.03 g/mol) , ΔvapH is enthalpy of 
vaporisation (100 kJ/mol), σ is surface tension and rd is droplet radius. 
 The predicted elevated boiling temperature for PFB particles of varying diameter is shown in 
Figure 7a for surface tensions ranging from 5 – 20 mN/m, covering expected values for 
fluorocarbon droplets and bubbles 49. For PFB particles at room temperature with diameters 
between 100 - 200 nm the majority lie below the vaporisation curve and would be expected to 
exist as liquid droplets. Previous work in our group has also shown that our NB sample 
experiences a rapid increase in size, measured via Dynamic Light Scattering, when heated above 
a threshold temperature of 57 °C suggesting the occurrence of a phase transition from liquid to 
gas. 27 This transition temperature matches closely to the predicted value in Figure 7a for a 
surface tensions of 10-15 mN/m. Additionally, we see that the predicted vaporisation 
 
Figure 7. (a) Vaporisation temperature of a PFB droplet with varying surface tension 
calculated using the Clausius-Clapeyron relationship (Equation 4). (b) Predicted final 
bubble diameter after vaporisation of a PFB droplet comparing 3 models documented from 
48. 

























































temperature for these values lie within the range of temperatures measured during our CW HIFU 
release exposures (Figure S5), supporting the hypothesis of a phase-change release trigger.  
To determine whether droplet vaporisation would be capable of inducing liposomal drug 
release, a model developed by Evans et al 48 was used to predict the expected diameter increase 
of the resultant bubble post vaporisation. There are 3 models with increasing complexity, which 
we have labelled as elementary, developed and intermediate. Briefly, the developed model 
accounts for a change in solubility of the core after vaporisation, whereas the elementary model 
neglects this. The intermediate model adds additional complexity by assuming partial 
equilibration of the core with a surrounding region around the particle. The predicted bubble size 
post-vaporisation is shown in Figure 7b for all three models, assuming a droplet surface tension 𝜎 = 10 mN/m and bubble surface tension 𝜎 = 20 mN/m.  For droplets of 100 – 200 nm 
diameter, all models produced similar results with expected bubble diameter post vaporisation of 
> 300 nm, i.e. larger than the modal size of our encapsulating liposomes, which suggests that this 




This study demonstrated the diagnostic and therapeutic potential of Nested-NBs. 
Perfluorobutane NBs were co-loaded with model-drug into liposomes less than 300nm in 
diameter. The resultant Nested-NBs displayed good echogenicity at clinically relevant imaging 
frequencies (3-8 MHz). Triggered release was investigated using continuous and pulsed HIFU. 
Pulsed HIFU led to NB destruction but did not lead to significant drug release. In contrast, 
continuous-wave HIFU produced drug release across a range of PNPs. We can understand our 
observations if, at room temperature, our Nested-NBs contain a mix of both encapsulated PFB 
 22
NBs and PFB droplets. During continuous wave HIFU the sample temperature was also found to 
increase above a predicted threshold such that the PFB droplets underwent a phase-change from 
the liquid to gas state. The subsequent increase their diameter, by a factor of 3, led to liposome 
rupture and drug release. Thus Nested-NBs have both diagnostic potential, providing contrast 
enhancement for clinically relevant ultrasound frequencies, as well as the ability to trigger drug 
release through a the vaporisation of PFB droplets.  
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